These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 25963745)

  • 1. Assessing cost-effectiveness of HPV vaccines with decision analytic models: what are the distinct challenges of low- and middle-income countries? A protocol for a systematic review.
    Ekwunife OI; Grote AG; Mosch C; O'Mahony JF; Lhachimi SK
    Syst Rev; 2015 May; 4():68. PubMed ID: 25963745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations.
    Ekwunife OI; O'Mahony JF; Gerber Grote A; Mosch C; Paeck T; Lhachimi SK
    Pharmacoeconomics; 2017 Jan; 35(1):65-82. PubMed ID: 27637758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Health economic evaluation of human papillomavirus vaccines in the developing countries: systematic reviews].
    Song X; Mao F; Zhou Z; Zhao Q; Fang Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Jan; 50(1):85-90. PubMed ID: 26792509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review.
    Wong CKH; Liao Q; Guo VYW; Xin Y; Lam CLK
    Vaccine; 2017 May; 35(24):3153-3161. PubMed ID: 28476628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend.
    Gervais F; Dunton K; Jiang Y; Largeron N
    BMC Public Health; 2017 Mar; 17(1):283. PubMed ID: 28351348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Influencing the Cost-Effectiveness Outcomes of HPV Vaccination and Screening Interventions in Low-to-Middle-Income Countries (LMICs): A Systematic Review.
    Okeah BO; Ridyard CH
    Appl Health Econ Health Policy; 2020 Oct; 18(5):641-654. PubMed ID: 32468410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of human papilloma virus vaccination in low and middle income countries: a systematic review of literature.
    Silas OA; Achenbach CJ; Murphy RL; Hou L; Sagay SA; Banwat E; Adoga AA; Musa J; French DD
    Expert Rev Vaccines; 2018 Jan; 17(1):91-98. PubMed ID: 29183182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ecological validity of cost-effectiveness models of universal HPV vaccination: a protocol for a systematic review.
    Favato G; Noikokyris E; Vecchiato R
    Syst Rev; 2017 Jan; 6(1):17. PubMed ID: 28118846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries.
    Simonella L; Canfell K
    Vaccine; 2015 Jan; 33(1):34-51. PubMed ID: 25171843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Human Papilloma Virus (HPV) vaccination in Nigeria: a decision analysis using pragmatic parameter estimates for cost and programme coverage.
    Ekwunife OI; Lhachimi SK
    BMC Health Serv Res; 2017 Dec; 17(1):815. PubMed ID: 29216880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: A systematic review.
    Mezei AK; Armstrong HL; Pedersen HN; Campos NG; Mitchell SM; Sekikubo M; Byamugisha JK; Kim JJ; Bryan S; Ogilvie GS
    Int J Cancer; 2017 Aug; 141(3):437-446. PubMed ID: 28297074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
    Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
    Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.
    Ben Hadj Yahia MB; Jouin-Bortolotti A; Dervaux B
    Clin Drug Investig; 2015 Aug; 35(8):471-85. PubMed ID: 26187455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review.
    Saokaew S; Rayanakorn A; Wu DB; Chaiyakunapruk N
    Pharmacoeconomics; 2016 Dec; 34(12):1211-1225. PubMed ID: 27510721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries.
    Campos NG; Sharma M; Clark A; Lee K; Geng F; Regan C; Kim J; Resch S
    Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():47-56. PubMed ID: 28691334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for cervical cancer prevention in Asia Pacific.
    Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
    Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.